ArticleCureus2024
Intravenous Immunoglobulin and Intravenous Acyclovir as an Alternative Therapy to Varicella Zoster Immunoglobulin in the Prevention of Serious Complications of Neonatal Varicella.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neonatal varicella zoster transmission from mother, management in a resource-limited setting: A case report.World journal of clinical pediatrics · 2026Article
- Neonatal varicella and early-onset herpes zoster following maternal infection at term: a case report.Journal of medical case reports · 2026Article
- Varicella Zoster Virus Infection and Pregnancy: An Optimal Management Approach.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal varicella, arising from maternal infection with the varicella-zoster virus (VZV), is a rare but potentially severe condition with diverse clinical presentations. This case report highlights an instance where the mother developed a maculopapular rash seven days before delivery, indicating a possible transmission of VZV to the neonate. The patient's family history included recent diagnoses of herpes zoster and varicella among household members. On the second day of life, the newborn developed a discrete vesicular rash on an erythematous background, affecting the trunk and neck. Due to the unavailability of varicella zoster immunoglobulin (VZIG), intravenous immunoglobulin (IVIG) was administered along with a seven-day course of intravenous acyclovir. Despite the absence of VZIG, the combined treatment with IVIG and acyclovir proved effective in resolving the rash by the sixth day of life, without any ensuing complications. This case underscores the challenges of managing neonatal varicella in resource-limited settings and suggests that combination therapy may not prevent the occurrence of neonatal varicella but can mitigate serious complications and expedite clinical recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.